December 2025 SCRI Release Copied
SCRI Trials and Trial Regimen Updates
The following updates were completed between Nov. 14 – Dec. 11, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.
For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 25157 | USOR 25157 GI 430 Phase 3 PF-08634404 or Bevacizumab + mFOLFOX6 Q28D – 16Oct2025 |
| 25034 | USOR 25034 GU 276 Phase 2 Arm A AAA617 + ARPI Q42D – v00 24JAN2025 USOR 25034 GU 276 Phase 2 Arm A ARPI Q84D- v00 24JAN2025 USOR 25034 GU 276 Phase 2 Arm A Randomization ARPI – v00 24JAN2025 USOR 25034 GU 276 Phase 2 Arm B AAA617 Q42D – v00 24JAN2025 |
| 24256 | USOR 24256 GYN 142 Phase 3 Arm A T-DXd + Bevacizumab Q21D – v3.0 04DEC2024 USOR 24256 GYN 142 Phase 3 Arm B Bevacizumab Q21D – v3.0 04DEC2024 |
| 24299 | USOR 24299 GYN 143 Phase 2 Post-IDS Mirvetuximab soravtansine + Carboplatin +/- Bevacizumab Q21D – v3.0 25AUG2025 USOR 24299 GYN 143 Phase 2 Pre-IDS Mirvetuximab soravtansine + Carboplatin Q21D – v3.0 25AUG2025 |
| 24305 | USOR 24305 LUN 601 Phase 3 Afatinib Q21D – v1.0 15MAY2025 USOR 24305 LUN 601 Phase 3 Firmonertinib Q21D – v1.0 15MAY2025 USOR 24305 LUN 601 Phase 3 Osimertinib Q21D – v1.0 15MAY2025 |
| 25091 | USOR 25091 LUN 630 Phase 3 Arm A PF-08046054 Q21D – 28May2025 USOR 25091 LUN 630 Phase 3 Arm B Docetaxel Q21D – 28May2025 |
| 24168 | USOR 24168 MM 152 Phase 3 Arm A Teclistamab + Lenalidomide Q28D v7.0 21JUN2024 USOR 24168 MM 152 Phase 3 Arm B Lenalidomide Q28D v7.0 21JUN2024 USOR 24168 MM 152 Phase 3 Arm C Teclistamab Q28D v7.0 21JUN2024 |
| 24209 | USOR 24209 RM 1007 Phase 1a TOS-358 Q21D – v6.2 07MAY2025 USOR 24209 RM 1007 Phase 1b TOS-358 + Fulvestrant + CDK4/6i Q28D – v6.2 07MAY2025 USOR 24209 RM 1007 Phase 1b TOS-358 + Fulvestrant Q28D – v6.2 07MAY2025 |
| RM 1307 MCCR | M 1307 Phase 1 AXN-2510 Q21D – v1.3 17OCT2025 |
| 24304 | USOR 24304 RM 905 Phase 1 Part B JZP815 Q28D – 03AUG2024 |
| 25037 | USOR 25037 RM 1000 Phase 2 TNG260 + Pembrolizumab Q21D – v3.0 07MAR2024 |
| 24197 | USOR 24197 CLL 61 Phase 2 Pirtobrutinib Q28D – 30MAY2025 |
| 25176 | USOR 25176 GU 303 Phase 1b/2 Cohort A PF-08634404 Q21D – 17Sep2025 USOR 25176 GU 303 Phase 1b/2 Cohort B PF-08634404 + Ipilimumab Q21D – 17Sep2025 USOR 25176 GU 303 Phase 1b/2 Cohort C PF-08634404 + Axitinib Q21D – 17Sep2025 |
| RM 1199 MCCR | RM 1199 Phase 1 Part A Rezatapopt + Repaglinide + Midazolam + Metformin + Rosuvastatin D1-24 – v1 18JUL2025 RM 1199 Phase 1 Part B Rezatapopt Q21D – v1 18JUL2025 |
| 24205 | USOR 24205 LYM 248 Phase 2 Arm 1 Zilovertamab vedotin + R-CHP Q21D – 05JUN2025 USOR 24205 LYM 248 Phase 2 Arm 2 Polatuzumab vedotin + R-CHP Q21D – 05JUN2024 |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes |
| 21498 | Version 6.0; 25 Feb 2025 | N/A | N/A | Update Drug; Instructions |
| 23122 | Version 3.0; 19 Sept 2025 | N/A | Regimen Comments; Admin | Update Drug; Instructions, premedication |
| 23328 | Version 3.0; 18 July 2025 | N/A | Regimen Comments; Admin, Prophylaxis | Update Drug; Instructions |
| 24026 | PM v4.0; 30 July 2025 | N/A | N/A | Update drug; instructions |
| 24208 | PM v2.0; 03 November 2025 | N/A | N/A | Update drug; admin/prep, instructions |
| 24259 | PM v3.0; 12 November 2025 | N/A | N/A | Update drug; instructions |
| 24299 | PA v3.0: 25 Aug 2025 | N/A | Regimen Comments; Prophylaxis | Added; Drug |
| 24320 | PM v3.0; 06 October 2025 | N/A | N/A | Update Drug; Dose/Form |
| 25018 | Version 4.0; 23 June 2025 | N/A | Regimen Comments; admin, observation | Update drug; instructions, admin/prep |
| 25109 | PM v3.0; 20 October 2025 | N/A | N/A | Update drug; admin/prep |
| RM 1307 MCCR | Version 1.3; 17 October 2025 | N/A | Regimen Comments; Observation | N/A |
| 24112 | PA3: 14 Jun 2025 | N/A | N/A | Update drug; instructions |
| 24075 | PM v5.0; 17 October 2025 | N/A | N/A | Update drug; instructions |
| 24153 | Version 2.0, 29JAN2025 | N/A | Regimen comments; Admin | Update Drug; premedication |
| 23245 | PM v1.0: 31 Oct 2025 | N/A | N/A | Update drug; instructions |
| 23240 | PA v7.0; 15 July 2025 | N/A | Regimen comments; prophylaxis | Update drug; instructions |
| 24130 | Need to reactivate Cohort 2 Arms 1 and 3 (currently only Cohort 2 Arm 2 is active per outdated memo) 12/5 Site error these regimens are no longer needed. | N/A | N/A | Update drug; admin/prep, premedication |
| 24006 | PM v2.0; 20 November 2025 | N/A | N/A | Update drug; instructions |
| 24130 | PCL; 29 Sept 2025 | N/A | N/A | Update drug; admin/prep, instructions |
| 23294 | Amendment 5, 04Mar2025 | N/A | Regimen Comments; Prophylaxis | Update Drug; admin/prep, premedication |
| 22090 | DIL; 09 April 2025 DIL; 08 July 2025 PA v5.0; 11 July 2025 DIL; 14 August 2025 |
N/A | Regimen comments; admin | Update Drug; dose/form, instructions, procurement |